Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $8.9900 (0.22%) ($8.7900 - $9.1200) on Mon. Feb. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.63% (three month average) | RSI | 58 | Latest Price | $8.9900(0.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) IBB(10%) XBI(10%) EWI(9%) | Factors Impacting ADMS price | ADMS will decline at least -1.815% in a week (0% probabilities). BNDX(-11%) UUP(-9%) GLD(-7%) GDX(-7%) GDXJ(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.815% (StdDev 3.63%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
5 Day Moving Average | $9.05(-0.66%) | 10 Day Moving Average | $8.96(0.33%) | 20 Day Moving Average | $8.84(1.7%) | To recent high | -22% | To recent low | 16% | Market Cap | $254m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |